Results 161 to 170 of about 23,919 (200)
Some of the next articles are maybe not open access.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1986
Aztreonam is a new, totally synthetic beta‐lactamase agent — the first monobactam. It is highly resistant to hydrolytic inactivation caused by plasmid‐mediated (except PSE‐2 enzyme found in some Pseudomonas species) or chromosomally mediated beta‐lactamases (except for K1 produced by rare strains of Klebsiella oxytoca).
S J, Childs, G P, Bodey
openaire +3 more sources
Aztreonam is a new, totally synthetic beta‐lactamase agent — the first monobactam. It is highly resistant to hydrolytic inactivation caused by plasmid‐mediated (except PSE‐2 enzyme found in some Pseudomonas species) or chromosomally mediated beta‐lactamases (except for K1 produced by rare strains of Klebsiella oxytoca).
S J, Childs, G P, Bodey
openaire +3 more sources
Toward Orally Absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part 2 [PDF]
ACS Medicinal Chemistry Letters, 2020 Aztreonam, first discovered in 1980, is an FDA approved, intravenous, monocyclic beta-lactam antibiotic. Aztreonam is active against Gram-negative bacteria and is still used today. The oral bioavailability of aztreonam in humans is less than 1%.
Matthew Duncton, Eric Gordon
exaly +2 more sources
AZTREONAM COMPARED WITH GENTAMICIN FOR TREATMENT OF SERIOUS URINARY TRACT INFECTIONS [PDF]
Lancet, The, 1984 52 patients with serious urinary tract infections were randomised to receive either aztreonam (35) or gentamicin (17). In the aztreonam group 23 patients had unqualified cures, 6 cures with relapse, and 6 cures with reinfection; the comparable numbers in
P C Appelbaum
exaly +1 more source
Nature Reviews Drug Discovery, 2010
In February 2010, aztreonam for inhalation solution (Cayston; Gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.
O'Sullivan, Brian P. +2 more
openaire +3 more sources
In February 2010, aztreonam for inhalation solution (Cayston; Gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.
O'Sullivan, Brian P. +2 more
openaire +3 more sources
Obstetrics and Gynecology Clinics of North America, 1992
Aztreonam is a synthetic monobactam antibiotic that has excellent activity against aerobic gram-negative bacilli. It can be used as a single agent for the treatment of upper urinary tract infections caused by organisms resistant to the cephalosporins and ampicillin.
openaire +3 more sources
Aztreonam is a synthetic monobactam antibiotic that has excellent activity against aerobic gram-negative bacilli. It can be used as a single agent for the treatment of upper urinary tract infections caused by organisms resistant to the cephalosporins and ampicillin.
openaire +3 more sources
The Pediatric Infectious Disease Journal, 1989
Monocyclic beta-lactam antibiotics (monobactams) are structurally unique from the traditional bicyclic beta-lactams because of their single ring configuration. Aztreonam, the first of these monobactams, has been studied extensively in order to determine its pharmacologic and pharmacokinetic profile in adults and children with bacterial infections.
openaire +2 more sources
Monocyclic beta-lactam antibiotics (monobactams) are structurally unique from the traditional bicyclic beta-lactams because of their single ring configuration. Aztreonam, the first of these monobactams, has been studied extensively in order to determine its pharmacologic and pharmacokinetic profile in adults and children with bacterial infections.
openaire +2 more sources
Drug Intelligence & Clinical Pharmacy, 1985
Aztreonam is the first synthetic monobactam to undergo clinical studies in the U.S. Aztreonam has excellent activity against P. aeruginosa and Enterobacteriaceae, but poor activity against anaerobic and gram-positive organisms. Aztreonam has poor oral bioavailability, but can be given intramuscularly or intravenously in doses of 1–2 g q6–12h.
openaire +2 more sources
Aztreonam is the first synthetic monobactam to undergo clinical studies in the U.S. Aztreonam has excellent activity against P. aeruginosa and Enterobacteriaceae, but poor activity against anaerobic and gram-positive organisms. Aztreonam has poor oral bioavailability, but can be given intramuscularly or intravenously in doses of 1–2 g q6–12h.
openaire +2 more sources
Infectious Disease Clinics of North America, 1989
To date, clinical use of aztreonam has been remarkably restrained and widespread enthusiasm for addition to hospital formularies similarly moderate. Its most accepted indication appears to be in gram-negative bacillary infections in the penicillin-allergic individual where one might ordinarily use an extended spectrum penicillin or a third generation ...
openaire +2 more sources
To date, clinical use of aztreonam has been remarkably restrained and widespread enthusiasm for addition to hospital formularies similarly moderate. Its most accepted indication appears to be in gram-negative bacillary infections in the penicillin-allergic individual where one might ordinarily use an extended spectrum penicillin or a third generation ...
openaire +2 more sources